Spinal muscular atrophy (SMA) is a neurodegenerative disease that causes loss of motor neurons, results in paralysis, and in the most severe forms leads to death. The incidence of SMA is 1 in 10,000 live births, making this disease one of the leading causes of infant mortality. SMA is caused by low levels of the survival motor neuron (SMN) protein. Recent experiments have shown a remarkable rescue of phenotype in SMA mice upon delivery of SMN using scAAV9. Likewise, correction of SMN2 splicing using antisense oligonucleotides (ASO) can expand survival and rescue electrophysiology defects. Such promising pre-clinical studies have led to several clinical trials for the treatment of SMA. It is crucial that biomarkers are established for SMA that can help predict treatment response and to measure therapeutic effect. A panel of protein markers known as SMA- MAP shows correlation with function in SMA patients. Yet, it is unknown if these markers can quantify therapeutic response. A subset of these plasma markers are both abnormal in SMA mice and normalize in SMA mice treated presymptomatically with anti-sense oligonucleotides (ASO) to increase SMN. The ability of these markers to quantify treatment response following treatment with ASO to increase SMN will be tested in SMA mice treated at different disease stages. These findings will be further investigated by testing the SMA- MAP panel in blood samples from treated SMA type I infants enrolled in the phase 1 gene therapy clinical trial at our center. These samples will be compared with samples from untreated SMA type 1 infants, matched for age and SMN2 copy number, from the NeuroNext clinical trial to allow determination of the markers that respond to treatment. While SMN therapies are very effective when given early, they are less effective late in the course of disease.
In aim 2, combinatorial therapies to improve muscle function in combination with SMN therapies, will be tested in SMA mice. Mutations in the troponin C gene that result in increased calcium sensitivity will be delivered using adeno associated virus (AAV) vectors and tested for an effect on muscle contraction force even with reduced motor neuron input. Self-complementary AAV follistatin will be used to increase muscle mass to determine if there is an additive effect of increased muscle size when combined with SMN. In these combinatorial therapy experiments, mice will be treated with ASOs to increase SMN at different disease stages to mimic the clinical trial situation. We will monitor muscle force and electrophysiological measures of motor unit function in these mice. Finally, aim 3 will investigate whether higher levels of SMN can enhance motor neuron repair and improve therapeutic response in post symptomatically treated mice. Lastly intron 6 and 7 will be investigated using the CRISPR/Cas9 system to find new regulatory sites that control splicing of exon 7. Identification of new sites will expand therapeutic targets that can be used with ASOs and open the possibility of using AAV vector to make a permeant change in SMN2.

Public Health Relevance

Spinal muscular Atrophy is a leading genetic cause of infant death. We investigate biomarker which can respond to SMN therapy and thus allow monitoring of when therapies work. We start to explore therapy for SMA latter in the disease with a combination of SMN inducers and muscle enhancers. Last we look at combined SMN therapies to maximize the response to SMN inducer as well as knew target sequences in SMN2.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD060586-08
Application #
9691728
Study Section
National Institute of Child Health and Human Development Initial Review Group (CHHD)
Program Officer
Parisi, Melissa
Project Start
2009-07-17
Project End
2022-04-30
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
8
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Ohio State University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Arnold, W; McGovern, Vicki L; Sanchez, Benjamin et al. (2016) The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy. Neurobiol Dis 87:116-23
Arnold, W David; Duque, Sandra; Iyer, Chitra C et al. (2016) Normalization of Patient-Identified Plasma Biomarkers in SMN?7 Mice following Postnatal SMN Restoration. PLoS One 11:e0167077
McGovern, Vicki L; Iyer, Chitra C; Arnold, W David et al. (2015) SMN expression is required in motor neurons to rescue electrophysiological deficits in the SMN?7 mouse model of SMA. Hum Mol Genet 24:5524-41
McGovern, Vicki L; Massoni-Laporte, Aurélie; Wang, Xueyong et al. (2015) Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity in the ?7 SMA Mouse. PLoS One 10:e0132364
Iyer, Chitra C; McGovern, Vicki L; Murray, Jason D et al. (2015) Low levels of Survival Motor Neuron protein are sufficient for normal muscle function in the SMN?7 mouse model of SMA. Hum Mol Genet 24:6160-73
Iyer, Chitra C; McGovern, Vicki L; Wise, Dawnne O et al. (2014) Deletion of atrophy enhancing genes fails to ameliorate the phenotype in a mouse model of spinal muscular atrophy. Neuromuscul Disord 24:436-44
Arnold, W David; Porensky, Paul N; McGovern, Vicki L et al. (2014) Electrophysiological Biomarkers in Spinal Muscular Atrophy: Preclinical Proof of Concept. Ann Clin Transl Neurol 1:34-44
Arnold, W David; Burghes, Arthur H M (2013) Spinal muscular atrophy: development and implementation of potential treatments. Ann Neurol 74:348-62
Mitrpant, Chalermchai; Porensky, Paul; Zhou, Haiyan et al. (2013) Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS One 8:e62114
Porensky, Paul N; Burghes, Arthur H M (2013) Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum Gene Ther 24:489-98

Showing the most recent 10 out of 13 publications